In Brief: Abbott Outlook; CFSAN’s Landa To Retire; FTC Claim Substantiation

Abbott “on track” in China recovery; CFSAN seeks new director; FTC adds new substantiation elements to settlement; NAD advises iSatori to amend claims energy supplement claims; FDA wants proof deficiencies are corrected; and FDA warns about chelation supplement.